Colorectal Cancer NGS Panel
The CRC NGS panel contains the 43-gene mutation panel and the 45-gene methylation panel. The mutation panel detects actionable mutations for targeted therapy, helping patients with metastatic colorectal cancer (mCRC) to improve outcomes. The methylation panel hel[s identification of the CRC origin and increases the test’s clinical sensitivity and specificity.
Research Use Product
CLIA-Certified Lab Service
Research Service
Introducing OptiSeq™ Colorectal Cancer NGS Panel
OptiSeq ™ Colorectal cancer NGS Panel determines genetic alterations in diagnosed colorectal cancer patients for actionable target therapy selections, according to the NCCN (National Comprehensive Cancer Network) guidelines.
In addition, the methylation panel targets a total of 434 CpG sites across 61 genomic regions in 45 methylation markers associated with CRC.
Simple blood test: 3 tubes of blood needed
Mutation panel covers 43 genes and 462 genetic alterations; Methylation panel detects 434 methylation sites within 45 genes
100% clinical sensitivity and 100% clinical specificity based on the samples we tested
Who will benefit from OptiSeq™?
The OptiSeq™ Cancer NGS Panel covers the detection of KRAS (codons 12,13,59,61,117 and 146), NRAS (codons 12,13,59,61,117 and 146), BRAFV600E, ERBB2 amplification, and microsatellite instability covered in the NCCN (National Comprehensive Cancer Network) guideline for metastatic colorectal cancer (mCRC) targeted therapy.
CLIA Labs
CLIA labs that value and validate the panel for targeted therapy selection
Clinical Studies/Trial
Clinical studies or clinical trials that use this panel to profile CRC patients before and/or after drug testing.
Once colorectal cancer is diagnosed, using clinical NGS to identify actionable genetic alterations is critical for targeted therapy.
Although monoclonal antibodies against EGFR, such as cetuximab and panitumumab, can be used to treat patients to control colorectal cancer cell growth, patients with mutations present in other RAS/RAF genes, for instance, will not respond to the anti-EGFR therapy.
The NCCN ((National Comprehensive Cancer Network)) guidelines recommend the following tests:
All patients with mCRC should be tested for NRAS/KRAS and BRAF mutations
MSI testing is recommended for patients with mCRC
Trastuzumab and pertuzumab therapy option is added for ERBB2 amplification and wildtype RAS patients
The DiaCarta Offerings
PRODUCT
- OptiSeq™ Colorectal Cancer NGS Panel is a research use product.
- Pack size is 24-reaction.
- Catalog Number: DC-50-0005R.
SERVICE
OptiSeq™ Colorectal Cancer NGS Panel is available at DiaCarta CLIA as a Lab-Developed-Test (LDT) or a research use test.